Considerations in the Development of Stereoisomeric Drugs: FDA Viewpoint
- 1 October 1989
- journal article
- Published by Springer Nature in Drug Information Journal
- Vol. 23 (4) , 663-667
- https://doi.org/10.1177/009286158902300420
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: